Carcinosarcoma of the ovary: A review

Obstetrical and Gynecological Survey

Volumn 64, Issue 10, 2009, Pages 673-680

  Cantrell, Leigh A ^a   Van Le, Linda ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL; PLATINUM; TRABECTEDIN;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CYTOREDUCTIVE SURGERY; ENDOMETRIUM BIOPSY; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; OVARIAN CARCINOSARCOMA; PROGNOSIS; REVIEW; RISK FACTOR; UTERINE CARCINOSARCOMA; UTERINE CERVIX CARCINOSARCOMA; VAGINAL CARCINOSARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 73249132730     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181b8aff3     Document Type: Review

References (49)

1. George E, Marvivel JC, Dehner LP. Malignant mixed mullerian tumors: an immunochemical study of 47 cases with histogenetic considerations and clinical correlation. Hum Pathol 1991;22:215-223.
2. Jin Z, Ogata S, Tamura G, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003;22:368-373. (Pubitemid 37152987)
3. Schipf A, Mayr D, Kirchner T, et al. Molecular genetic aberra- tions of ovarian and uterine carcinosarcomas-a CGH and FISH study. Virchows Arch 2008;452:259-268.
4. Sonoda Y, Saigo PE, Gederici MG, et al. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. Gynecol Oncol 2000;76:226-229. (Pubitemid 30067201)
5. Gallardo A, Matias-Guiu X, Lagarda H, et al. Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases. Int J Gynecol Pathol 2002;21:268-272. (Pubitemid 34680344)
6. Doss LL, Llorens AS, Henriquez EM. Carcinosarcoma of the uterus: a 40-year experience from the state of Missouri. Gynecol Oncol 1984;18:43-53.
7. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumors when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gyn 1992;99: 490-594.
8. Zelmanowicz A, Hildesheim A, Sherman ME, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69:253-257. (Pubitemid 28289969)
9. Iwasa Y, Haga H, Konishi I, et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 1998;82:512-519. (Pubitemid 28112990)
10. Jonson AL, Bliss RL, Truskinovsky A, et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol 2006;100:561-564. (Pubitemid 43246873)
11. Meredith RJ, Eisert DR, Kaka Z, et al. An excess of uterine sarcomas after pelvic irradiation. Cancer 1986;58:2003-2007. (Pubitemid 16008775)
12. Creasman WT, Phillips JL, Menck HR. The national cancer data base report on cancer of the vagina. Cancer 1998;83: 1033-1040.
13. Curtin JP, Saigo P, Slucher B, et al. Soft-tissue sarcoma of the vagina and vulva: a clinicopathologic study. Obstet Gynecol 1995;86:269-272.
14. Peters WA, Kumar NB, Andersen WA, et al. Primary sarcoma of the adult vagina: a clinicopathologic study. Obstet Gynecol 1985;65:699-704. (Pubitemid 15123944)
15. Clement PB, Zubovits JT, Young RH, et al. Malignant mullerian mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with morphology often different from its counterpart in the corpus. Int J Gynecol Pathol 1998;17:211-222.
16. Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004;100:2148-2153.
17. Silverman JF, Gardner J, Larkin EW, et al. Ascitic fluid cytology in a case of metastatic malignant mixed mesodermal tumor of the ovary. Acta Cytol 1986;30:173-176. (Pubitemid 16051008)
18. Barholtz-Sloan J, Bryant C, Morris R, et al. Survival of women diagnosed with malignant mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93:506-512. (Pubitemid 38507626)
19. Harris MA, Delap LM, Sengupta PS, et al. Carcinosarcoma of the ovary. Br J Cancer 2003;88:654-657.
20. Cho SB, Park CM, Park SW, et al. Malignant mixed mullerian tumor of the ovary: imaging findings. Eur Radiol 2001 ;11: 1147-1150.
21. Sood AK, Sorosky JI, Gelder MS, et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82:1731-1737.
22. Mok JE, Kim YM, Jung MH, et al. Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006;16:101-105.
23. George E, Lillemoe TJ, Twiggs LB, et al. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.
24. Athavale R, Thomakos N, Godrey K, et al. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy. Int J Gynecol Cancer 2007;17:1025-1030. (Pubitemid 47414830)
25. Nayha V, Stenback F. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. APMIS 2008;116:107-117.
26. Zorzou MP, Markaki S, Rodolakis A, et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005;96:136-142. (Pubitemid 39612428)
27. Liu F, Kohler MF, Marks JR, et al. Mutation and overexpression of the P53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994;83:118-124. (Pubitemid 24027393)
28. Inthasorn P, Beale P, Dalrymple C, et al. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust NZJ Obstet Gynaecol 2003;43:61-64.
29. Rutledge TL, Gold MA, McMeekin DS, et al. Carcinosarcoma of the ovary-a case series. Gynecol Oncol 2006;100:128-132.
30. Leiser AL, Chi DS, Ishill NM, et al. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial SloanKettering Cancer Center experience. Gynecol Oncol 2007; 105:657-661.
31. Rebischung C, Pautier P, Morice P, et al. Alpha-fetoprotein production by a malignant mixed mullerian tumor of the ovary. Gynecol Oncol 2000;77:203-205. (Pubitemid 30217327)
32. Muntz HG, Jones MA, Goff BA, et al. Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer 1994;76:1209-1213.
33. Barakat RR, Rubin SC, Wong G, et al. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1990;80:660-664.
34. Plaxe SC, Dottine PR, Goodman HM, et al. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin and cisplatin-based chemotherapy. Gynecol Oncol 1990;37:244-249.
35. Terada KY, Johnson TL, Hopkins M, et al. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 1989;32:228-232.
36. Morrow CP, Bundy BN, Hoffman J, et al; A Gynecologic Oncology Group Study. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. Am J Clin Oncol 1986;9:24-26. (Pubitemid 16164707)
37. Anderson B, Turner DA, Benda J. Ovarian sarcoma. Gynecol Oncol 1987;26:183-192.
38. Duska LR, Garrett A, Eltabakh GH, et al. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2002;85:459-463.
39. Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22-29.
40. Cicin I, Saip P, Eralp Y, et al. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008; 108:136-140. (Pubitemid 350299436)
41. Piver NS, DeEulis TG, Lele SB, et al. Cyclophosphamide, vincristine, adriamycin and dimethyl-thazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol 1982;14:319-323.
42. Morrow CP, d'Ablaing G, Brady LW, et al; Gynecologic Oncology Group study. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors. Gynecol Oncol 1984;18:278-292.
43. Moore M, Fine S, Sturgeon J. Malignant mixed mesodermal (MMM) tumors of the ovary: the Princess Margareth Hospital (PMH) experience. Proc Am Soc Clin Oncol 1986;5:14.
44. Sit AS, Price FV, Kelley JL, et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 2000;79: 196-200. (Pubitemid 30822916)
45. Prendiville J, Murphy D, Renninson J, et al. Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital. Int J Gynecol Cancer 1994;4:200-205.
46. Chang J, Sharpe JC, A'Hern RP, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol 1995;6:755-758.
47. Crotzer DR, Wolf JK, Gano JB, et al. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 2007; 105: 399-403.
48. Sutton GP, Blessing JA, Homesley HD, et al; a Gynecologic Oncology Group study. A phase Il trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinumbased chemotherapy. Gynecol Oncol 1994;53:24-26.
49. Tate Thigpen J, Blessing JA, DeGeest K, et al; Gynecologic Oncology Group study. Cisplatin as initial chemotherapy in ovarian carcinosarcomas. Gynecol Oncol 2004;93:336-339.